What is the difference between Zepbound and Mounjaro?

Zepbound and Mounjaro are both tirzepatide. Same molecule, same manufacturer (Eli Lilly), same pen design. The only difference is the FDA indication printed on the label.

Which is better, Zepbound or Mounjaro?

It depends on your goals. Choose Zepbound for your primary diagnosis is obesity or overweight with comorbidity (on-label use). Choose Mounjaro for you have a type 2 diabetes diagnosis (on-label use, better insurance coverage).

Zepbound vs Mounjaro

Peptide Schedule Research TeamReviewed Apr 202626 Citations

Zepbound and Mounjaro contain the exact same active ingredient: tirzepatide, made by Eli Lilly. The difference is the FDA-approved indication. Zepbound is approved for chronic weight management (obesity). Mounjaro is approved for type 2 diabetes. Same drug, same pen design, different label.

Tirzepatide

Weight Loss~5 days

20.2% body weight gone at 72 weeks, and that was the average, not the ceiling. Tirzepatide (LY3298176, CAS 2023788-19-2) is a 39-amino acid acylated lipopeptide sold as Zepbound for obesity and Mounjaro for type 2 diabetes. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. The dual receptor mechanism separates tirzepatide from single-target GLP-1 drugs like semaglutide. GIP receptor activation improves fat metabolism and may reduce the nausea burden that limits GLP-1-only treatment. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and boosts insulin secretion. Those two pathways working together produce weight loss and glycemic control that neither achieves alone. SURMOUNT-1 (PMID 35658024, n=2,539) showed dose-dependent results at 72 weeks: 15.0% weight loss at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg. SURMOUNT-5 (PMID 40353578, n=751) ran a direct comparison; tirzepatide reached 20.2% versus semaglutide's 13.7%. Roughly one in five tirzepatide patients lost 30% or more of their body weight. The r/Zepbound community (180,000+ members) confirms what the trials found. Appetite suppression starts within days. Most users stabilize at 7.5 to 12.5 mg rather than pushing to the maximum 15 mg dose. Cost and insurance coverage remain the biggest barriers. Weight regain after stopping is well-documented; about two-thirds of lost weight returns within a year of discontinuation.

View full guide →

Tirzepatide

Weight Loss~5 days

View full guide →

At a Glance

Attribute	Tirzepatide	Tirzepatide
Category	Weight Loss	Weight Loss
Safety Grade	B	B
Half-Life	~5 days	~5 days
Route	Subcutaneous	Subcutaneous
Vial Sizes	5mg, 10mg, 15mg	5mg, 10mg, 15mg
Beginner Dose	2500mcg Weekly	2500mcg Weekly
Moderate Dose	5000mcg Weekly	5000mcg Weekly
Aggressive Dose	10000mcg Weekly	10000mcg Weekly
Dosing Source	FDA Label	FDA Label
Side Effects	Tirzepatide carries a black box warning for thyroid C-cell tumors. In rodent studies, it caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this translates to humans is unknown, and no confirmed human cases have been attributed to tirzepatide. The drug is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Gastrointestinal side effects are the most common reason people struggle with tirzepatide. In the SURMOUNT and SURPASS trials, nausea affected 17 to 25% of patients (dose-dependent, worst during dose escalation). Diarrhea occurred in 13 to 17%. Vomiting hit 8 to 10%. Constipation affected 7 to 11%. Most of these effects are mild-to-moderate and improve with slow dose titration; the community-preferred 6 to 8 week steps between dose increases reduce GI burden compared to the FDA label's 4-week minimum. Decreased appetite (9 to 11%) is technically a side effect, though most users consider it the primary benefit. Sulfur burps are a community-reported nuisance during escalation phases that clinical trials don't track well. Hair thinning (telogen effluvium) affects roughly 4 to 5% of users versus about 1% on placebo. This isn't a direct drug effect. Rapid weight loss and caloric restriction trigger a hair growth cycle shift that typically starts 2 to 3 months in and resolves on its own by month 9 to 12. Injection-site reactions occur in 4 to 7% of patients. Rotating injection sites between the abdomen, thigh, and upper arm helps. Let the vial reach room temperature for 15 to 20 minutes before injecting. Pancreatitis is rare but serious. Severe, persistent abdominal pain warrants immediate medical evaluation. Serum lipase testing should happen only when pancreatitis is clinically suspected; routine screening isn't indicated. Gallbladder disease and hypersensitivity reactions are uncommon but documented in clinical trials. Stop tirzepatide and seek medical care if you develop signs of anaphylaxis, severe abdominal pain, or jaundice. Muscle loss is a legitimate concern. Approximately 25% of weight lost on tirzepatide is lean mass (SURMOUNT-1 body composition data). Resistance training 3 to 4 times per week and protein intake of at least 1.2 g/kg body weight per day are the primary countermeasures. Pregnancy and breastfeeding: tirzepatide is contraindicated. Stop treatment at least 2 months before planned conception due to the 5-day half-life and limited reproductive safety data.	Tirzepatide carries a black box warning for thyroid C-cell tumors. In rodent studies, it caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this translates to humans is unknown, and no confirmed human cases have been attributed to tirzepatide. The drug is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Gastrointestinal side effects are the most common reason people struggle with tirzepatide. In the SURMOUNT and SURPASS trials, nausea affected 17 to 25% of patients (dose-dependent, worst during dose escalation). Diarrhea occurred in 13 to 17%. Vomiting hit 8 to 10%. Constipation affected 7 to 11%. Most of these effects are mild-to-moderate and improve with slow dose titration; the community-preferred 6 to 8 week steps between dose increases reduce GI burden compared to the FDA label's 4-week minimum. Decreased appetite (9 to 11%) is technically a side effect, though most users consider it the primary benefit. Sulfur burps are a community-reported nuisance during escalation phases that clinical trials don't track well. Hair thinning (telogen effluvium) affects roughly 4 to 5% of users versus about 1% on placebo. This isn't a direct drug effect. Rapid weight loss and caloric restriction trigger a hair growth cycle shift that typically starts 2 to 3 months in and resolves on its own by month 9 to 12. Injection-site reactions occur in 4 to 7% of patients. Rotating injection sites between the abdomen, thigh, and upper arm helps. Let the vial reach room temperature for 15 to 20 minutes before injecting. Pancreatitis is rare but serious. Severe, persistent abdominal pain warrants immediate medical evaluation. Serum lipase testing should happen only when pancreatitis is clinically suspected; routine screening isn't indicated. Gallbladder disease and hypersensitivity reactions are uncommon but documented in clinical trials. Stop tirzepatide and seek medical care if you develop signs of anaphylaxis, severe abdominal pain, or jaundice. Muscle loss is a legitimate concern. Approximately 25% of weight lost on tirzepatide is lean mass (SURMOUNT-1 body composition data). Resistance training 3 to 4 times per week and protein intake of at least 1.2 g/kg body weight per day are the primary countermeasures. Pregnancy and breastfeeding: tirzepatide is contraindicated. Stop treatment at least 2 months before planned conception due to the 5-day half-life and limited reproductive safety data.

Key Differences

Zepbound and Mounjaro are both tirzepatide. Same molecule, same manufacturer (Eli Lilly), same pen design. The only difference is the FDA indication printed on the label.
Zepbound is FDA-approved for chronic weight management in adults with BMI 30+ (or 27+ with comorbidity). Mounjaro is FDA-approved for type 2 diabetes as an adjunct to diet and exercise.
Insurance coverage is the main practical difference. Mounjaro is covered under most diabetes formularies. Zepbound coverage for obesity is inconsistent, with many plans excluding weight loss medications entirely.
Mounjaro launched in June 2022 at doses up to 15 mg. Zepbound launched in November 2023. Mounjaro has a longer prescribing track record, though all safety data applies to both since the molecule is identical.
Prescribing for off-label use is common. Some providers prescribe Mounjaro off-label for weight loss when Zepbound coverage is denied. This is legal but creates insurance billing complexity.

When to Choose Zepbound

Your primary diagnosis is obesity or overweight with comorbidity (on-label use)
Your insurance plan covers obesity medications but not diabetes drugs you don't need
You want the weight management indication on your medical record
Your provider prefers prescribing on-label for the specific condition being treated